看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 0.0x - 0.0x | 0.0x |
| Selected Fwd EBIT Multiple | 0.0x - 0.0x | 0.0x |
| Fair Value | $0.91 - $0.92 | $0.92 |
| Upside | 38.4% - 39.1% | 38.7% |
| Benchmarks | Ticker | Full Ticker |
| Dyadic International, Inc. | DYAI | NasdaqCM:DYAI |
| Onconetix, Inc. | ONCO | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | CRDF | NasdaqCM:CRDF |
| Geron Corporation | GERN | NasdaqGS:GERN |
| Trevena, Inc. | TRVN | PINC:TRVN |
| Spero Therapeutics, Inc. | SPRO | NasdaqGS:SPRO |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| DYAI | ONCO | CRDF | GERN | TRVN | SPRO | ||
| NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | PINC:TRVN | NasdaqGS:SPRO | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 28.2% | -0.2% | -7.1% | 10.4% | 6.9% | -370.6% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -441.2% | -7788.4% | -7896.4% | -24589.2% | -15325.1% | -386.7% | |
| Prior Fiscal Year | -282.6% | NA | -9305.7% | -81832.9% | 13486.8% | 25.8% | |
| Latest Fiscal Year | -168.2% | -27161.9% | -7123.1% | -225.6% | -1129.2% | -151.1% | |
| Latest Twelve Months | -168.2% | -735.2% | -7123.1% | -225.6% | -5880.0% | -151.1% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 9.13x | 9.37x | 145.01x | 7.11x | 46.15x | -0.27x | |
| EV / LTM EBITDA | NA | -1.3x | -2.1x | -3.2x | -0.8x | 0.2x | |
| EV / LTM EBIT | -5.4x | -1.3x | -2.0x | -3.2x | -0.8x | 0.2x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -5.4x | -2.0x | -0.8x | ||||
| Historical EV / LTM EBIT | -5.1x | -4.7x | 0.2x | ||||
| Selected EV / LTM EBIT | 0.0x | 0.0x | 0.0x | ||||
| (x) LTM EBIT | (72) | (72) | (72) | ||||
| (=) Implied Enterprise Value | 1 | 1 | 1 | ||||
| (-) Non-shareholder Claims * | 49 | 49 | 49 | ||||
| (=) Equity Value | 49 | 49 | 49 | ||||
| (/) Shares Outstanding | 55.9 | 55.9 | 55.9 | ||||
| Implied Value Range | 0.88 | 0.88 | 0.88 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 0.88 | 0.88 | 0.88 | 0.66 | |||
| Upside / (Downside) | 33.2% | 33.3% | 33.4% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | ONCO | CRDF | GERN | TRVN | SPRO | |
| Enterprise Value | 32 | 18 | 90 | 531 | 25 | (12) | |
| (+) Cash & Short Term Investments | 9 | 0 | 92 | 407 | 13 | 53 | |
| (+) Investments & Other | 0 | 0 | 0 | 95 | 0 | 0 | |
| (-) Debt | (5) | (10) | (2) | (122) | (38) | (4) | |
| (-) Other Liabilities | 0 | (7) | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 36 | 1 | 180 | 911 | 1 | 37 | |
| (/) Shares Outstanding | 30.1 | 8.3 | 66.5 | 636.9 | 0.9 | 55.9 | |
| Implied Stock Price | 1.21 | 0.08 | 2.71 | 1.43 | 1.28 | 0.66 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.21 | 0.08 | 2.71 | 1.43 | 1.28 | 0.66 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |